Comparative Preclinical Evaluation of Tuznue Versus Referent Herceptin: A Registered Trastuzumab Biosimilar.
- Published in:
- Drugs in R&D, 2025, v. 25, n. 1, p. 67, doi. 10.1007/s40268-025-00505-w
- By:
- Publication type:
- Article
Works matching IS 1174-5886 AND VI 25 AND IP 1 AND DT 2025
Results: 7
1
2
Analysis of Sirolimus Blood Concentration and Influencing Factors in Pediatric Patients: Implications for Individualized Drug Therapy.
- Published in:
- Drugs in R&D, 2025, v. 25, n. 1, p. 79, doi. 10.1007/s40268-025-00506-9
- By:
- Publication type:
- Article
3
A Real-World Data Analysis of Alglucosidase Alfa in the FDA Adverse Event Reporting System (FAERS) Database.
- Published in:
- Drugs in R&D, 2025, v. 25, n. 1, p. 57, doi. 10.1007/s40268-024-00502-5
- By:
- Publication type:
- Article
4
Characterization for the Similarity Assessment Between the Proposed Biosimilar SB17 and Ustekinumab Reference Product Using State-of-the-Art Analytical Methods.
- Published in:
- Drugs in R&D, 2025, v. 25, n. 1, p. 19, doi. 10.1007/s40268-024-00501-6
- By:
- Publication type:
- Article
5
Analyses of Adverse Drug Reactions to Fluoroquinolones in Spontaneous Reports Before and After the Referral and in Clinical Routine Cases.
- Published in:
- Drugs in R&D, 2025, v. 25, n. 1, p. 35, doi. 10.1007/s40268-024-00499-x
- By:
- Publication type:
- Article
6
Evaluation of BCRP-Related DDIs Between Methotrexate and Cyclosporin A Using Physiologically Based Pharmacokinetic Modelling.
- Published in:
- Drugs in R&D, 2025, v. 25, n. 1, p. 1, doi. 10.1007/s40268-024-00495-1
- By:
- Publication type:
- Article
7
Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.
- Published in:
- 2025
- By:
- Publication type:
- Correction Notice